Company News 09 Apr 2025 Orthocell Receives Regulatory Approval for Striate+ in Brazil Orthocell has announced that Brazilian Health Regulatory Agency, ANVISA, has granted regulatory approval for the Company’s market-leading dental membrane, Striate+â„¢,… Orthocell
Media 06 Apr 2025 MEDIA | 7 News Orthocell’s recent FDA clearance made headlines on 7 News this week, with journalist Alice Murray showcasing the human impact of… Orthocell
Media 05 Apr 2025 MEDIA | 9 News Orthocell welcomed 9 News journalist Michael Stamp to Orthocell HQ last week to film an in-depth segment about our FDA… Orthocell
Company News 04 Apr 2025 US FDA grants 510(k) clearance for Orthocell’s flagship Remplirâ„¢ nerve repair product Orthocell has announced that the US Food and Drug Administration has granted regulatory clearance under the 510(k) pathway for the… Orthocell
Company News 26 Mar 2025 First Sales of Striate+â„¢ in DACH Region Orthocell has today announced that our exclusive global distribution partner BioHorizons has officially completed first sales of Orthocell’s dental product,… Orthocell
Company News 18 Mar 2025 Orthocell Receives Regulatory Approval for Striate+ in Singapore Orthocell has received regulatory approval from Singapore's Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product,… Orthocell
Video 26 Feb 2025 REPLAY | Investor Webinar Orthocell CEO and MD, Paul Anderson, hosted a webinar this morning to provide an important update on Orthocell's clinical and… Orthocell
Company News 21 Feb 2025 Thailand Regulatory Application for Remplirâ„¢ Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device… Orthocell
Company News 03 Feb 2025 Orthocell Submits Canada Regulatory Application to Commence Sales of Remplirâ„¢ into US$75million Canadian market Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its… Orthocell
Media 23 Jan 2025 Stockhead | Orthocell soars 14% after crushing early sales growth for Remplir Orthocell's plans to broaden its commercial footprint in existing and new markets drove the company's share price up 13.8% this… Orthocell
